Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients

Documenti analoghi

• Favipiravir pharmacokinetics in Thai adults with mild COVID‐19: A sub‐study of interpatient variability and ethnic differences in exposure
  di: Ing‐orn Prasanchaimontri, et al.
  Pubblicazione: (2024)
• An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction
  di: Ryutaro Iwama, et al.
  Pubblicazione: (2024)
• The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
  di: Vanessa Martins, et al.
  Pubblicazione: (2024)
• A systematic review on experimental studies about patient adherence to treatment
  di: Frans Folkvord, et al.
  Pubblicazione: (2024)
• Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
  di: Wei Yin, et al.
  Pubblicazione: (2024)